RVMDRevolution Medicines, Inc.
$189.76+336% 1Y
$189.76
$42.5152 weeks$216.19
RVMD in its own filings
Nothing in RVMD's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
124
Events found in the filings · across 857 filings · the record starts in 2019
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 1, 2026
Most recent filing · Form 8-K
- Record starts
- Oct 16, 2019
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- SEC comment-letter activity20 occurrences
- 2024-04-26
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 1, 2026On August 27, 2026, Revolution Medicines, Inc. (the “Company”) agreed to lease the entirety of four buildings located at 1600, 1700, 1800 and 1900 Seaport Boulevard in Redwood City, California, comprising an aggregate of approximately 672,000 rentable square feet (collectively, the “Premises”)Material agreement entered · Form 8-K
- Aug 26, 2026On August 26, 2026, the U.S. Food and Drug Administration approved RASONQUE™ (daraxonrasib) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy (the “FDA Approval”)Other event · Form 8-K
- Aug 5, 2026Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress.Earnings release · press release
- Jun 22, 2026On June 18, 2026, Steve Kelsey, M.D., FRCP, FRCPath, informed Revolution Medicines, Inc. (the “Company”) of his intent to retire from his employment with the Company effective as of January 4, 2027.Director or officer change · Form 8-K
- May 6, 2026Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress.Earnings release · press release
- Apr 17, 2026On April 17, 2026, Revolution Medicines, Inc. (the “Company”) issued $500,000,000 aggregate principal amount of its 0.50% Convertible Senior Notes due 2033 (the “Notes”)Material agreement entered · Form 8-K
- Apr 16, 2026Equity Offering On April 14, 2026, Revolution Medicines, Inc. (the “Company”) entered into an underwriting agreement (the “Equity Underwriting Agreement”) with J.P. Morgan Securities LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (collectively …Other event · Form 8-K
- Apr 13, 2026On April 13, 2026, Revolution Medicines, Inc. (the “Company”) shared topline results from its global, randomized, controlled Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (“PDAC”) who had been previously treated.Other event · Form 8-K
- Feb 25, 2026Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress.Earnings release · press release
- Nov 5, 2025Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress.Earnings release · press release
- Oct 17, 2025On October 16, 2025, Revolution Medicines, Inc. (the “Company”) announced that the U.S. Food and Drug Administration has granted the Company a non-transferrable voucher for daraxonrasib, the Company’s RAS(ON) multi-selective inhibitor, under the Commissioner’s National Priority Voucher pilot program.Other event · Form 8-K
- Sep 10, 2025On September 10, 2025, Revolution Medicines, Inc. (the “Company”) provided the following pipeline updates.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…